Harnessing the Power of Heat to Fight Cancer
Systemic Perfusion Hyperthermia is an innovative cancer treatment that uses controlled elevation of body temperature to target and weaken cancer cells. By mimicking the body’s natural fever response, this therapy activates immune defenses while making malignant cells more vulnerable to treatment.
Why Hyperthermia Works
Fever is one of the body’s natural defense mechanisms. It helps the immune system identify and fight abnormal cells, including cancer. However, cancer cells can sometimes evade this response.
Hyperthermia enhances this natural process by safely raising the body’s temperature to levels that cancer cells cannot tolerate. While healthy cells remain resilient, malignant cells become unstable and more susceptible to destruction.
How Systemic Perfusion Hyperthermia Works
This advanced technique involves circulating and heating the blood in a controlled environment to gradually increase the body’s core temperature.
- Cancer cells become more permeable and vulnerable
- Tumor cells release antigens, improving immune recognition
- The body’s immune response is activated and strengthened
- Anti-cancer therapies become more effective
The entire process is closely monitored using specialized equipment to ensure safety, precision, and optimal therapeutic outcomes.
A Unique and Advanced Technology
Our system uses a computer-controlled perfusion process to precisely regulate temperature and blood flow. This allows for:
- Rapid and controlled heating of the body
- Continuous monitoring of vital signs
- Elimination of human error through automated control
- Safe and consistent treatment delivery
Patients remain awake and comfortable throughout the procedure, without the need for sedation.
Types of Hyperthermia Treatments
- Regional Hyperthermia: Targets a specific area of the body
- Systemic Hyperthermia: Treats the entire body for widespread impact
Systemic Perfusion Hyperthermia offers a comprehensive approach, making it ideal for addressing cancer at a systemic level.
The Heckel Whole-Body Hyperthermia System
In addition to systemic perfusion hyperthermia, the Immunotherapy Institute uses the Heckel hyperthermia system, a medical-grade whole-body hyperthermia device built by Heckel Medizintechnik, a German manufacturer that has specialized in whole-body hyperthermia systems since 1994.
The Heckel system uses water-filtered infrared-A (wIRA) radiation, a specific band of infrared energy that penetrates below the skin surface. Rather than only heating the skin, the absorbed heat is carried through the whole body by the bloodstream, producing an even, systemic rise in core temperature. Every session is temperature-monitored from start to finish, and the treatment team adjusts intensity and duration to the individual patient.
We already use Heckel hyperthermia in our Lyme program. Adding it to our oncology protocols applies the same established heating technology to a different treatment target: making tumors more responsive to chemotherapy and immunotherapy. It is added alongside active cancer treatment, not in place of it.
How Does Hyperthermia Work with Chemotherapy?
Raising core body temperature into a controlled therapeutic range changes how tumor cells respond to treatment. Heat stresses cancer cells, makes their membranes more permeable, and improves blood flow and oxygenation in tumor tissue, which can improve drug delivery into the tumor itself.
Whole-body hyperthermia combined with chemotherapy has been studied in clinical trials for more than two decades. Phase I and II studies, most using temperatures around 41.8°C, have combined whole-body hyperthermia with regimens such as oxaliplatin, leucovorin and 5-fluorouracil in metastatic colorectal cancer. More recently, the first-in-human MATTERS trial, published in 2026, found that repeated whole-body hyperthermia at 41.5°C was generally tolerable and did not show a clear increase in serious adverse events when added to standard chemotherapy in patients with advanced solid tumors.
Reported results vary between studies and patient groups, and controlled phase III evidence is still limited. Published reviews describe whole-body hyperthermia as a promising addition that needs randomized trials, and that is how we position it as well: an added layer on top of active treatment, never a substitute for it.
Can Hyperthermia Be Combined with Immunotherapy?
Yes. Heat and immune response are closely connected, and this combination is an active area of published research.
- Heat shock proteins. Heated tumor cells release heat shock proteins that help flag them for recognition by the immune system. This is part of what can turn an immunologically “cold” tumor into one the immune system engages with more actively.
- Immunogenic cell death. Hyperthermia promotes a form of cell death that releases signals capable of recruiting and activating immune cells, in contrast to the silent cell death that leaves the immune system uninvolved.
- Measured immune activation. A clinical study of whole-body hyperthermia at 41.8°C added to chemotherapy measured prolonged T cell activation and changes in natural killer cell activity that were not seen in patients who received chemotherapy alone.
- Checkpoint therapy. Research on hyperthermia combined with checkpoint-targeting therapies reports reduced inhibitory checkpoint signals, increased dendritic cell maturation and greater T cell infiltration into tumor tissue. A phase II study combined water-filtered infrared-A whole-body hyperthermia with a PD-1 checkpoint inhibitor in advanced gastrointestinal cancers and found increased immune-activated cells in tumors after hyperthermia.
At the Immunotherapy Institute this fits directly into how our oncology program is built: metronomic-dose targeted therapy alongside autologous cellular immunotherapy using dendritic cells, NK cells and activated lymphocytes prepared from the patient’s own blood. Hyperthermia is positioned to help both components work better, not to replace either one.
What Does the Research Show?
Peer-reviewed studies have evaluated hyperthermia combined with chemotherapy and immune checkpoint therapy across several cancer types:
- A 2024 systematic review and meta-analysis covering 782 rectal cancer patients across 12 studies found that adding deep regional hyperthermia to neoadjuvant chemoradiotherapy was associated with meaningful pathologic response and long-term survival outcomes.
- A 2026 retrospective study in advanced squamous non-small cell lung cancer found a significantly higher objective response rate when deep hyperthermia was added to a PD-1 checkpoint inhibitor plus chemotherapy, with no increase in treatment-related adverse events.
- A 2025 retrospective study in advanced cervical cancer found that adding hyperthermia to targeted therapy and chemoradiotherapy improved short-term response and reduced targeted-therapy side effects.
- Mechanistic and narrative reviews from 2025 and 2026 summarize how regional and whole-body hyperthermia can make tumors more responsive to combined radiotherapy, chemotherapy and immunotherapy by altering the tumor microenvironment.
These studies describe results from their own patient populations and protocols. They are cited here as representative published research, not as a report of Immunotherapy Institute outcomes or a promise of what any individual patient will experience.
Whether hyperthermia is appropriate for a given patient, and at what intensity, is a medical determination made during the full case evaluation, alongside diagnosis, prior treatment history and the current clinical picture.
Benefits of Systemic Perfusion Hyperthermia
- Weakens and targets cancer cells through heat sensitivity
- Enhances immune system activation
- Improves effectiveness of complementary therapies
- Provides precise control over body temperature
- Reduces pain and inflammation through immunomodulation
- Allows longer, more effective treatment sessions without sedation
A Safer, More Effective Approach to Cancer Care
Systemic Perfusion Hyperthermia represents a powerful advancement in integrative oncology. By working with the body’s natural defenses and enhancing other therapies, it offers patients a more comprehensive and supportive path in their cancer treatment journey.